US Genu Recurvatum Market

ID: MRFR/Pharma/17489-HCR 100 Pages Satyendra Maurya Last Updated: September 10, 2026
United States Genu Recurvatum Market Research Report By Type (Structural Genu Recurvatum, Functional Genu Recurvatum, Neuromuscular Genu Recurvatum) By Severity (Mild, Moderate, Severe) By Treatment Method (Surgical Intervention, Physical Therapy, Orthotic Management, Rehabilitative Care) By Patient Demographics (Pediatric, Adult, Geriatric) - Growth & Industry Forecast 2025 To 2035
US Genu Recurvatum Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.7%
2024 Market Size$ 157.5 Million
2025 Market Size$ 164.9 Million
2035 Market Size$ 261 Million
Key Players
Smith & Nephew
Stryker Corporation
Zimmer Biomet
DePuy Synthes
Medtronic
Ottobock
Opportunities
  • Growing Geriatric Population
  • Advancements in Orthotic Devices
  • Increasing Incidence of Genu Recurvatum
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Type (USD Million)
      1. 4.1.1 Structural Genu Recurvatum
      2. 4.1.2 Functional Genu Recurvatum
      3. 4.1.3 Neuromuscular Genu Recurvatum
    2. 4.2 Pharmaceutical, BY Severity (USD Million)
      1. 4.2.1 Mild
      2. 4.2.2 Moderate
      3. 4.2.3 Severe
    3. 4.3 Pharmaceutical, BY Treatment Method (USD Million)
      1. 4.3.1 Surgical Intervention
      2. 4.3.2 Physical Therapy
      3. 4.3.3 Orthotic Management
      4. 4.3.4 Rehabilitative Care
    4. 4.4 Pharmaceutical, BY Patient Demographics (USD Million)
      1. 4.4.1 Pediatric
      2. 4.4.2 Adult
      3. 4.4.3 Geriatric
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Smith & Nephew (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Stryker Corporation (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Zimmer Biomet (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 DePuy Synthes (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Medtronic (IE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Ottobock (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Apex Medical (TW)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Breg (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY SEVERITY
    4. 6.4 US MARKET ANALYSIS BY TREATMENT METHOD
    5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY SEVERITY, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY SEVERITY, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY TREATMENT METHOD, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY TREATMENT METHOD, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY SEVERITY, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT METHOD, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US US Genu Recurvatum Market Segmentation

US Genu Recurvatum Market By Type (USD Million, 2025-2035)

  • Structural Genu Recurvatum
  • Functional Genu Recurvatum
  • Neuromuscular Genu Recurvatum

US Genu Recurvatum Market By Severity (USD Million, 2025-2035)

  • Mild
  • Moderate
  • Severe

US Genu Recurvatum Market By Treatment Method (USD Million, 2025-2035)

  • Surgical Intervention
  • Physical Therapy
  • Orthotic Management
  • Rehabilitative Care

US Genu Recurvatum Market By Patient Demographics (USD Million, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.